Advancing healthcare resilience after COVID-19

On Tuesday, 25 October, AmCham EU hosted its annual healthcare plenary on ‘Advancing Healthcare Resilience as a response to the COVID-19 pandemic’ featuring a keynote address from Céline Gauer, Head of the Recovery and Resilience Task Force, European Commission. Gauer highlighted the need for reforms and investments both in primary care as well as on a structural level. She also emphasised that the private and public sectors need to work together to ensure sustainability in healthcare, and to promote development in cancer research.

News

27 Oct 2022

Healthcare

HomePolicy and newsLibraryAdvancing healthcare resilience after COVID-19

A panel focusing on the question of healthcare policy after COVID also took place. Panellists highlighted that, following the pandemic, the EU has taken concrete steps to create more resilient healthcare system, including in the form of the Recovery and Resilience Faculty. The discussion was moderated by Felix Uedelhoven (GE-Healthcare), Vice-Chair, Healthcare Committee, AmCham EU and featured the following guest speakers:  

Frederico Guanais, PhD, Deputy Head, Health Division, Directorate for Employment, Labour and Social Affairs, Organisation for Economic Co-operation and Development (OECD)
Tomislav Sokol MEP (EPP, HR)

For further background, please read our paper on the Digital Healthcare and our latest Transatlantic Economy Report. 

Related items

News

20 May 2026

Healthcare, competitiveness, innovation and simplification

Europe’s life sciences sector sits at the heart of the EU’s competitiveness agenda. It supports advanced manufacturing and helps bring new treatments and technologies to patients. Yet companies deciding where to invest need a regulatory environment that is predictable and open to global cooperation.

The European Commission’s work on the Biotech Act and the targeted revision of the Medical Devices and In Vitro Diagnostics Regulations (MDR/IVDR) offers an opportunity to improve that environment. Both files can help make Europe a stronger location for life sciences investment.

The EU should use this moment to build a framework that keeps pace with scientific progress. That means faster and clearer procedures. It also means better use of data and intellectual property rules that recognise the realities of global supply chains.

Healthcare

Simplification